"New Test Enhances Immunotherapy Access for Mismatch Repair-Deficient Cancers"
Originally Published 2 years ago — by UPI News
Researchers advocate for updated testing guidelines to include next-generation sequencing, which could identify an additional 6,000 U.S. cancer patients eligible for immunotherapy. This more sensitive test detects mismatch repair deficiency—a condition that makes certain cancers responsive to immunotherapy—more effectively than current immunohistochemistry tests. The study, published in the journal Cell, suggests that broader use of this advanced testing could lead to better treatment outcomes for patients with cancers like colon and endometrial cancer.